Healthy trend: Indian pharma firms see rise in USFDA drug approvals in FY18

Ahmedabad-headquartered Cadila Healthcare has received the largest number of approvals, at 76, so far in FY18

As FY18 enters its final quarter, a look at formulation approvals by the US Food and Drug Administration (FDA) in the year till date (YTD) period shows an improvement over the last year.

Deepak Malik, associate director at Edelweiss Securities, says that 750-800 approvals had come in 2016-17. In 2017-18, around 1,000 abbreviated new drug applications (ANDAs) to FDA are likely to get approval. "So far, around 700 or so approvals have come for ANDAs, and the last quarter is expected to see another 300 or so," he said. 

Of the major companies that sell drugs in that country, Ahmedabad-headquartered